Login

Tag: drug pricing blueprint

drug pricing blueprint

Courts/First Amendment

Court Rules Mandatory Drug Price Disclosure Rule Invalid, Stating CMS Lacks Statutory Authority

Court Rules Mandatory Drug Price Disclosure Rule Invalid, Stating CMS Lacks Statutory Authority

July 9, 2019 – One day before the Centers for Medicare & Medicaid Services’ (CMS’) final rule requiring drug companies to disclose the wholesale acquisition cost (WAC) or “list price” of their drugs in television ads was due to go into effect, the U.S. District Court for the District of Columbia issued a memorandum opinion […]

Read more

Washington Focus

Rawson: Drug Pricing Concerns Will Dominate in Run-up to 2020 Election

Rawson: Drug Pricing Concerns Will Dominate in Run-up to 2020 Election

May 23, 2019 – Concern over drug pricing remains a healthcare policy issue that enjoys bipartisan support and will remain on the table for the Trump administration and Congress as campaigns for the 2020 election ramp up, according to Kate Rawson, senior editor at Prevision Policy. Speaking at a session of the Coalition for Healthcare […]

Read more

Categories

Recent Posts

Tags

ACA ad tax CDER chc CMS coalition for healthcare communication conflict of interest Congress COVID-19 data privacy data privacy legislation DDMAC drug prices in DTC ads drug pricing DTC DTC advertising DTC advertising FDA FDA Commissioner FDA Draft Guidance FDA enforcement FDA social media FTC HHS Jim Potter John Kamp Jon Bigelow kamp Kate Rawson legislation litigation off-label off-label communication OPDP OPDP enforcement PhRMA privacy regulation rx data Scott Gottlieb social media sunshine act Untitled Letter Warning Letter Wayne Pines